AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Retained Earnings · Q3 FY2025 · quarter ended Sep 2025
Retained earnings of -€164.27M in Q3 FY2025
Q3 FY2025 retained earnings was -€164.27M.
Context
- Retained earnings amounted to 99.2% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
Currency unavailable · from the balance sheet
No Retained Earnings data reported for this period type.
Retained Earnings vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Retained earnings amounts to 99.2% of total assets for AGMB, versus a peer median of 300.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | -€164.27M EUR | — | — | 99.2% |
| Mar 2026 | -$221.52M USD | -9.4% | — | 351.2% | |
| Mar 2026 | -$825.44M USD | -3.4% | — | 250.4% | |
| Mar 2026 | -$987.61M USD | -7.6% | — | 497.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$1.14B USD | -62.9% | — | 202.8% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -8.5% | — | 300.8% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.